Description: This session will uncover the mystical findings that can be uncovered when leveraging a reinsurer. Insights discussed during this session include mortality at high face amounts, interactions between lapses and mortality, mortality improvement on low face amounts, fully underwritten mortality by Resident State and more. At the conclusion of this session, attendees will be able to identify where reinsurer data can help uncover insights, how mortality and lapse knowledge can improve product performance and what some mortality results can come from reinsurance research.

Description: At the conclusion of the first part, attendees will be able to describe sources of reserve redundancy for products under Principle Based Reserve (PBR) and products under Commissioners' Annuity Reserve Valuation Method (CARVM). Such products include Term Life, Whole Life, Universal Life, and Fixed Annuity with and without rider. We will also review sources of capital redundancy from the C-1 factor under Risk-Based Capital (RBC) and assets such as Unrated Asset Credit Fund can have high C-1 factor even if its risks are limited. At the conclusion of the second part, the attendees will learn about potential Reserve Relief reinsurance solutions. Such solutions can provide Reserve Relief for annuity and term life businesses, as well as potential innovative asset-side solutions. Asset managers can structure assets that the C-1 factor aligned with the corresponding risk.

Description: This session will27601 summarize the key National Association of Insurance Commissioners (NAIC) activities with a primary focus on updates to principle-based reserve valuations and appointed actuary topics. Hear insights into the current set of activities and initiatives being considered and/or adopted by the NAIC Life Actuarial Task Force (LATF) and the NAIC Risk Based Capital Working Group. In addition, other actuarial practice issues and other appointed actuary and opinion topics relevant to life insurance, variable annuities and fixed annuities will be discussed, including recent exposures and adoptions by the Actuarial Standards Board. By the end of the session, attendees will understand what changes are being made to reserves, RBC, PBR and actuarial standards and related topics, and the anticipated timing of such emerging changes.

Description: A panel of leading reinsurance executives provide perspective on topics to include cell and gene therapy, structured reinsurance, reinsurance demand for value based care arrangements, and how reinsurers view a variety of risk transfer opportunities.

Description: A panel of leading reinsurance executives will provide an overview of the health reinsurance market that explores existing reinsurance transactions reported under Schedule S, large claim research drawing insight from the latest five-year Merative Commercial MarketScan Research Database, stop-loss reinsurance options for Accountable Care Organizations (ACOs), and other reinsurance applications being seen in the market.

Description: There are a variety of regulatory changes that are being contemplated by the National Association of Insurance Commissioners (NAIC) that have the potential to materially impact actuarial, statutory reporting and disclosure requirements relating to reinsurance. This session will provide an introduction to these changes, explaining both the motivation as well as the potential impact these proposed changes may have on US ceding companies. The focus of the presentation will be primarily on changes affecting Asset Adequacy Testing and statutory risk transfer for combination Coinsurance / Yearly Renewable Term agreements. An update will be provided regarding industry responses to proposed changes and the potential timing for implementation of these new requirements.

Description: With recent and continuing changes in regulatory requirements under VM-20, new accounting standards under GAAP LDTI/IFRS 17, expansion of accelerated underwriting programs and digital distribution, and the impact of COVID-19, the needs and challenges being faced by life insurance companies are greater and more varied than ever. Both under favorable and stressed conditions, companies heavily rely on reinsurance and the market has seen several major transactions enacted in this space over recent months. Reinsurance offers a wider variety of opportunities for companies to manage their balance sheets and increase their return on capital. Find out how reinsurance can be utilized to address the challenges associated with earnings growth and volatility, risk management, capital allocation efficiency, and product performance optimization. Moreover, upon enacting a transaction, ensuring the implementation of effective reinsurance operations is crucial to avoid operational inefficiencies and monitor the transaction's performance. Understanding the potential opportunities and common pitfalls in the reinsurance processes is vital for capturing the full value of reinsurance. By attending the session, you will be able to understand the various challenges being faced by direct writing companies today and where reinsurance can be leveraged to improve capital and tax position, as well as achieving the optimal balance of risk appetite and underwriting profit. Additionally, the presentation will provide real life case studies on how innovation and operational excellence can improve earnings by reducing costs related to inefficiencies, reducing process timing, improving controls, and reducing reinsurance leakage.

Description: Over the last 10 years, Artificial Intelligence (AI) healthcare foundation models have made tremendous strides when it comes to delivering highly accurate predictive results when compared to traditional models. This is especially true for models developed and trained on the ‘language’ of healthcare. When trained on healthcare data sequences (claims, EHR, CPT, ICD, pharmacy, lab, etc.), these models deliver far more accurate results as to WHAT beneficiary-level health events will occur and even WHEN they will occur.

Description: Our understanding of the biology of aging is increasing rapidly, creating insight into how and why any organism is aging. Some of the mechanisms by which the process of aging occurs in mammals are sufficiently well understood that clinical trials targeting them in humans to improve later life health and longevity are now being undertaken. Translating results seen in mammals to humans has the potential to increase life expectancy far beyond what we have seen historically. Come explore the current state and outlook of research.

Description: "Demographic components of Future Potential Old-Age Support Ratios – Kirill Andreev, Ph.D., United Nations, Population Division, New York, Mila Andreeva, KAMA Consulting Effect of internal Migration on the Health of Taiwan’s Elderly People – Jack C. Yue, Ph.D., – National Chengchi University, Department of Statistics, Taipei, TaiwanPopulation Aging and Canada’s Social Contract: Covid-19 Catalyst for Change – Douglas Andrews, FSA, FCIA, Ph.D., Lori J. Curtis, Ph.D., – University of Waterloo"